RSV vaccine study for older adults in Sweden
Part of Immune system & allergy clinical trials.
This study tests a vaccine called Arexvy to see if it protects older adults from RSV, a virus that can cause serious lung infections. You must be born between 1965 and 1960 or before 1945, live in Sweden, and be medically stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were born between 1965 and 1960, or before 1945.
- You live in Sweden and can understand and read Swedish.
- You are medically stable, even if you have a condition like diabetes or high blood pressure.
- You have never received an RSV vaccine before.
- You are not taking strong immune-suppressing drugs or have a weakened immune system.
- You can agree to receive the Arexvy vaccine and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
This study tests how well an RSV vaccine (Arexvy) works in people whose immune systems are weakened by certain cancers, autoimmune diseases, or treatments. It aims to see if the vaccine can protect these vulnerable groups from respiratory infections.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study will safely expose healthy older adults (65-75) to a mild RSV B virus to see how their immune system responds. It may help develop better vaccines or treatments for RSV in older people.
Hear when a new RSV Immunisation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.